Acute Myeloid Leukemia (AML) linked to Benzene exposure

Acute Myeloid Leukemia (AML) linked to Benzene exposure. The American Cancer Society is reporting that work place exposure to the chemical substance BENZENE can cause Acute Myeloid Leukemia (AML). In a January 2016 report, the American Cancer Society chronicled several lab and clinical studies which strongly correlate exposure to Benzene to Acute Myeloid Leukemia. The report also suggests exposure to the chemical may be linked to several other blood cancers but the research is not conclusive at this point. Here’s more from the American Cancer Society web site: “Benzene is a colorless, flammable liquid with a sweet odor. It evaporates quickly when exposed to air. Benzene is formed from natural processes, such as volcanoes and forest fires, but most exposure to benzene results from human activities. Benzene is among the 20 most widely used chemicals in the United States. It is used mainly as a starting material in making other chemicals, including plastics, lubricants, rubbers, dyes, detergents, drugs, and pesticides. In the past it was also commonly used as an industrial solvent (a substance that can dissolve or extract other substances) and as a gasoline additive, but these uses have been greatly reduced in recent decades. Benzene is also a natural part of crude oil and gasoline (and therefore motor vehicle exhaust.)” Common Work Place Exposure to Benzene. Workers in industries that make or use benzene may be exposed to this chemical. These include the rubber industry, oil refineries, chemical plants, shoe manufacturers, and gasoline-related industries. Benzene is also used to make some types of lacs logoubricants, dyes, detergents, drugs, and pesticides. Other people who may be exposed to benzene at work include steel workers, printers, lab technicians, gas station employees, and firefighters. Federal regulations limit exposure to benzene in the workplace. Read more about the American Cancer Society’s report. If you, or a loved one, has been diagnosed with AML in the past five years we would like to review your situation to see if a causal link between Benzene exposure and AML can be established. Please contact attorney Knox Boteler at 866 975-7766 or by email at knox@bfw-lawyers.com. Please put Benzene Exposure Claim in the subject line of your email.   REQUIRED DISCLAIMERS: Alabama Rule of Professional Conduct 7.2: No representation is made that the quality of legal service to be performed is greater than the services provided by other lawyers. The Mississippi Supreme Court advises that a decision on legal services is important and should not be based solely on advertisements. Free background information is available upon request to a Mississippi attorney. The listing of any area of practice by a Mississippi attorney does not indicate any certification of expertise therein. See Mississippi Rules of Professional Conduct Rule 7.2(d), Rule 7.4(a), Rule 7.6(a) (1997). General Disclaimer: This information is posted for general information purposes to help those interested parties or persons with potential civil claims better understand their rights and potential causes of action. If readers are currently represented by an attorney on the subject matter of this post then they are encouraged to continue with said representation. No attorney-client relationship is established by this post.

Essure Birth Control Implant – Warning!

Essure Birth Control Implant – Warning! FDA warningEssure is a device sold as a permanent, non-surgical birth control solution for women. Manufactured by Bayer HealthCare Pharmaceuticals (Bayer) and approved by the Food & Drug Administration (FDA) in November, 2002, the Essure device consists of small, flexible coils that are placed into the fallopian tubes by a catheter. Once in place, the device is designed to elicit tissue growth in and around the coils to form blockage of the tubes. The tissue barrier formed prevents sperm from reaching an egg; thus, preventing conception. The FDA has received over 5,000 reports of severe complications and unwanted side-effects from patients implanted with Essure. These include pregnancy, ectopic pregnancy, miscarriage, perforation of the uterus or other organs, migration of the device or its components from the fallopian tubes to the lower abdomen and pelvis, severe menstrual cramps and abnormal and/or heavy bleeding, and even death, as some reports have claimed. Other reported effects include vaginal infection, bloating, fatigue, skin allergies, hair loss, chronic pain, headaches, weight gain, and depression, among others. Several women have reported persistent side-effects so severe that they required invasive surgery to remove the implanted device. It has been further reported that many women who have had adverse consequences are having trouble finding a doctor that will perform the complicated removal surgery. Others have experienced pain so severe that a hysterectomy was their only option for relief. Several lawsuits against Bayer are now pending in Courts across the United States alleging the pharmaceutical company intentionally misled women implanted with Essure regarding its safety and actively concealed negative reports about the adverse reactions reported about the device. On March 4, 2016, the FDA issued an update on the agency’s review of the Essure System. In that update, the agency ordered Bayer to conduct a post-market surveillance study to obtain more data about Essure’s benefits and risks. Additionally, the FDA gave notice of its intent to require an expanded warning with the product and provide a “Patient Decision Checklist” for the Essure System to help women understand the risks and benefits of the device. For now, though, the FDA will not consider removing the device from the U.S. market. If you or someone you love has developed side effects from the Essure Implant System, we would welcome an opportunity to review this situation and further discuss the status of these potential claims and cases. Call Attorney Knox Boteler toll free at 1 866 975-7766 or email: knox@bfw-lawyers.com.     REQUIRED DISCLAIMERS: Alabama Rule of Professional Conduct 7.2: No representation is made that the quality of legal service to be performed is greater than the services provided by other lawyers. The Mississippi Supreme Court advises that a decision on legal services is important and should not be based solely on advertisements. Free background information is available upon request to a Mississippi attorney. The listing of any area of practice by a Mississippi attorney does not indicate any certification of expertise therein. See Mississippi Rules of Professional Conduct Rule 7.2(d), Rule 7.4(a), Rule 7.6(a) (1997). General Disclaimer: This information is posted for general information purposes to help those interested parties or persons with potential civil claims better understand their rights and potential causes of action. If readers are currently represented by an attorney on the subject matter of this post then they are encouraged to continue with said representation. No attorney-client relationship is established by this post.

Dangers of Low Testosterone Therapy

Testosterone Replacement Therapy produLow Testosterone Therapy Riskscts for men have been linked to an increased risk of death, heart attack, stroke and blood clots. Testosterone therapy, such as the prescription topical treatments Androgel, Testim and Axiron, are used to help boost testosterone levels in men who have “Low T,” a deficiency of the male hormone. Call us today if you think you or a loved one may have a claim. Toll free at 1 866 975-7766. Or e-mail Mark Wolfe at mark@bfw-lawyers.com. Put “Low T Therapy Claim” in the subject line.

Synopsis of “Low Testosterone Treatment Risks” from Yahoo Health

New research indicates millions of men may be risking a heart attack, stroke or even premature death by taking testosterone therapy they don’t actually need.

Based on two large new studies linking approved prescription testosterone therapy to increased risk for cardiovascular events, the FDA has launched an investigation and cautions medical providers to carefully weigh if the benefits exceed the potential harms before prescribing these drugs, which are only advised for men who have low T and an associated medical condition.

In the latest study, published in the journal PLOS ONE and funded by the National Institutes of Health, researchers report that within 90 days, taking the hormone can more than double heart attack risk in men ages 65 and up—as well as nearly triple risk in younger men with known heart disease.

November, 2013 study published in Journal of the American Medical Association (JAMA) reported a 30 percent rise in risk for stroke, heart attack, and death in men age 60 and older who had been prescribed testosterone, compared to those who not.

“I’m very concerned that widespread use of testosterone supplements without any long-term safety studies is putting millions of men at risk for the most common lethal condition in the United States: heart disease,” says Steven Nissen, MD, department chair of Cardiovascular Medicine at the Cleveland Clinic.

“The FDA needs to require makers of these drugs to do long-term studies of these drugs, which are being marketed to men as a fountain of youth, just as hormone replacement therapy (HRT) was to women 20 years ago,” adds Dr. Nissen.

“When HRT was finally studied, it turned out to increase women’s risk for heart attack and stroke, and now the PLOS ONE study suggests that testosterone may have similar dangers for men,” says Dr. Nissen.

http://www.healthline.com/health-slideshow/healthy-heart-tips?utm_source=health.yahoo.net&utm_medium=referral&utm_campaign=yahhp

Treatments for low testosterone are now an estimated $2 billion-a-year industry in the US—with up to 25 percent of prescriptions written without medical providers bothering to do a blood test to check the man’s hormonal levels, according to the New York Times.

“Assuming that ‘low T’ is a huge global issue for all older men and prescribing the hormone without checking the man’s testosterone levels and cardiovascular risk is a scary—and highly irresponsible—practice,” says Amy Doneen, ARNP, medical director of the Heart Attack & Stroke Prevention Center in Spokane, Washington.

“Direct-to-consumer ads make it seem that if a man is tired and doesn’t have the libido he did at age 20, maybe the problem is ‘low T’,” reports Dr. Nissen, who feels that this problem may be greatly over-diagnosed. “The message men get is that these supplements are the fountain of youth they need, which is very seductive to men, but there isn’t much research to support these purported benefits.”

“What these well-done studies are telling us is that this treatment needs to be used cautiously in men who actually need it, after a careful, individualized assessment of both their symptoms and their cardiovascular health,” adds Doneen, who is also coauthor of Beat The Heart Attack Gene.

Currently, testosterone therapies, which have been FDA-approved for decades, don’t carry any cardiovascular warnings. The FDA is now investigating the link with heart attack, stroke, and early death identified in the new research.

Here’s a closer look at the studies and what men should know about testosterone-boosting drugs—available in at least five formulations, including gels, patches, and injections.

In the PLOS ONE study, the researchers compared rates of heart attacks in 55,593 middle-aged and older men in the 90 days after they received a new testosterone prescription with rates during the year prior to the initial prescription.

In addition, pre- and post-prescription heart attack rates were compared in a separate group of 167,279 men who were treated for erectile dysfunction with a type of medication known as phosphodiesterase type 5 inhibitors, such as Viagra and Cialis. This type of drug has not been linked to cardiac issues, so these men were studied as a control group.

The study found that among all men who received testosterone therapy, risk for non-fatal heart attack jumped by 36 percent in the 90 days after starting use of the hormone, compared to the rate of heart attack in these men during the one year prior to starting hormone treatment.

Among men age 65 an older, rate of heart attack soared by 219 percent in 90 days among those who received testosterone therapy, whether or not they had known heart disease. In men under 65, those with a prior history of heart disease had nearly triple the 90-day heart attack risk, compared to rates in the prior year.

“Men have higher rates of heart attacks than women do, and testosterone may be a factor, so there is a plausible biological explanation for the association between using these supplements and higher cardiovascular risk observed in the studies,” remarks Dr. Nissen.

To read the complete article: http://health.yahoo.net/experts/dayinhealth/testosterone-therapy-overhyped

If you or a loved one has suffered a heart attack, stroke and/or blood clots after starting testosterone therapy, you may be entitled to compensation for your injuries and damages. We can help. For more information, please contact Mark Wolfe of Boteler, Finley & Wolfe toll free at 1 866 975-7766 or by e-mail at mark@bfw-lawyers.com  [please place Low T Therapy Claim in the subject line]

 Learn more about Boteler, Finely & Wolfe. Learn more about Mark Wolfe’s experience and qualifications.

Required Disclaimers:

The Mississippi Supreme Court advises that a decision on legal services is important and should not be based solely on advertisements. Free Background information is available upon request to a Mississippi attorney. The listing of any area of practice by a Mississippi attorney does not indicate any certification of expertise therein. See Mississippi Rules of Professional Conduct Rule 7.2(d), Rule 7.4(a), Rule 7.6(a) (1997).

Alabama Rule of Professional Conduct 7.2: No representation is made that the quality of legal service to be performed is greater than the services provided by other lawyers.

General Disclaimer: This information is posted for general information purposes to help those interested parties or persons with potential civil claims better understand their rights and potential causes of action. If readers are currently represented by an attorney on the subject matter of this post then they are encouraged to continue with said representation. No attorney-client relationship is established by this post.

Polygrip Denture Cream

Polygrip Denture Cream’s manufacturer, GlaxoSmithKline, is under investigation for failing to inform users of this product’s potential safety risks. Polygrip Denture Cream contains 38 milligrams of zinc per ounce. Health experts recommend 8 milligrams of zinc per day for women and 11 milligrams for men. Medical studies have found excessive zinc may purge the body of copper, a chemical needed for normal brain and nervous system function. GlaxoSmithKline has announced that it will stop making Polygrip formulas containing zinc. Common side effects related to this product’s health risk include: loss of balance, loss of sensation in hands and feet and anemia. If you have any questions regarding your or a family member’s health and the use of Polygrip, please contact Knox Boteler at 866-975-7766 or email him at knox@bfw-lawyers.com for additional information. To learn more about this situation, click here.

Pradaxa warning! FDA investigating excess bleeding and death claims.

 Pradaxa (Dabigatran): Dabigatran is used to help prevent strokes or serious blood clots in people who have atrial fibrillation (a condition in which the heart beats irregularly, increasing the chance of clots forming in the body, and possibly causing strokes) without heart valve disease. Dabigatran is in a class of anticoagulant (”blood thinner”) medications called direct thrombin inhibitors.

Surgical Mesh Dangers for Transvaginal Pelvic Organ Prolapse Surgery Patients

Surgical Mesh: Manufactured by numerous companies including, Johnson & Johnson and Boston Scientific Corp.

Used for: Surgical repairs for Pelvic Organ Prolapse (POP) and/or Stress Urinary Incontinence (SUI) surgery. Used in place of stitches surgical mesh is designed to be a permanent implant and has been commonly used in transvaginal POP and SUI surgeries for many years. In POP procedures the mesh is commonly called a “bladder sling.”

Symptoms or Consequences: In July 2011, the FDA announced that a multi-year study of surgical mesh implants found serious complications associated with surgical mesh for POP and SUI procedures. The FDA report also noted, “[f]urthermore it is not clear that transvaginal POP repair with mesh is more effective than traditional non-mesh repair in all patients with POP and it may expose patients to greater risk.” Erosion of the mesh through the vagina is the most common and consistently reported complication. Mesh contraction is also a risk. Both mesh erosion and mesh contraction can cause severe pelvic pain, painful sexual intercourse. Other symptoms may include: Bladder, bowel, or blood vessel bleeding or perforation, bone and hip infections and/or the recurrence of the POP and/or SUI condition.

Additional Information: For more information visit Providence Health Plan

Contact: If you believe you or a loved one may have a claim related to the use of surgical mesh in a POP and/or SUI procedure, please contact Knox at Boteler, Finley & Wolfe (knox@bfw-lawyers.com) for more information and help locating the law firm leading these Mass Tort cases.

Actos linked to Bladder Cancer

Actos: Manufactured by: Takeda
Prescribed for: Actos (pioglitazone) is used in the treatment of diabetes. Actos is used to control blood sugar levels in patients with Type 2 diabetes, which keeps the body from producing enough insulin to properly use the sugar in the blood stream. Type 2 diabetes can also cause the patient to become resistant to insulin. Actos remedies this problem by making cells more sensitive to insulin, thereby making it easier for sugar to pass through the body.
Symptoms or Consequence: May cause bladder cancer. The Food and Drug Administration (FDA) mandated a warning be added to Actos packaging in 2007. A second FDA warning in June 2011 contained specific details of the risk of bladder cancer associated with Actos. A recent study of 193,099 patients over a five-year period found that people who took Actos for at least 12 months or longer were 40 percent more likely to develop bladder cancer. A subsequent FDA Adverse Event report found that Actos was involved in one-fifth of all reported diagnoses of bladder cancer in diabetes drug users.
Additional Information: Read more on this matter at Web MD, and the June 15, 2011 FDA report.
Contact: If you believe you or a loved one may have a claim related to the use of Actos and a diagnosis of bladder cancer, please contact Knox at Boteler, Finley & Wolfe (knox@bfw-lawyers.com) for more information and help locating the law firm leading these Mass Tort cases.